(Q37515438)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

review article

1 reference

title

Emerging molecular targeted therapies in the treatment of head and neck cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

Frédéric Peyrade

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Jean-Louis Fischel

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Gérard Milano

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

English

0 references

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

299-310

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus

30 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Free-flap head and neck reconstruction and quality of life: a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Promising new advances in head and neck radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Targeted therapies in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Promising newer molecular-targeted therapies in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Epidermal growth factor receptor inhibitors in cancer treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Epidermal growth factor receptor inhibitors enhance susceptibility to Fas-mediated apoptosis in oral squamous cell carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Modulation of cellular invasion by VEGF-C expression in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Ionizing radiation causes a dose-dependent release of transforming growth factor alpha in vitro from irradiated xenografts and during palliative treatment of hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Insulin-like growth factor receptor as a therapeutic target in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Current aspects of targeted therapy in head and neck tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Quantitative molecular diagnosis of axillary drainage fluid for prediction of locoregional failure in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

The activation of K-ras gene at an early stage of lung tumorigenesis in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

High frequency mutation in codons 12 and 61 of H-ras oncogene in chewing tobacco-related human oral carcinoma in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Immunohistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

ras mutations and expression in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210902997947

10.1517/14728210902997947

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19519286%20AND%20SRC:MED&resulttype=core&format=json

release_mpvrxi32rjcxroi2hot7cehode

30 January 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mpvrxi32rjcxroi2hot7cehode

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference